Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N° 59.382. Prospecto vigente aprobado por Disposición DI-2021-1038-APN-ANMAT#MS (05-Feb-2021)
Giangrande P. Karim F. Nemes L, et al. l ong-term safety and efficacy of NS-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2.J Thromb Hoemost. 2020;18(1):5-14.
Lentz SR. Kavalk.i K. Klamroth R, et al. Turoctocog alpha pegol (NB-GP) in severe hemophilia A: long,cerm safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Res Proct Thromb Haemost 2022;6(2):e12674.
Saulyte Trakymiene s. Economou M. Kc net G, Landorph A. Shen C, Kearney S. Long•term safety and efficacy of NS-GP in previously treated pediatric patients with hemophilia A: final results from pathfindetS.J Thromb Haemost. 2020;18(suppl 1):15-25.
Giangrande P. Andreeva T, Chowdary P. et al. Clinical evaluation of glycoPEGylated re,combinam FVUI: efficacy and safety in severe haemophilia A Thromb Hoemost. 2017;117(2):252-261.
Meunier S. Alamelu J. Ehrenforth S. et al. Safety and efficacy of a gtycoPEGylated rFV!ll (turoctocog alpha pegol. NS-GP) in paediatric patients with severe haemophilia A. Thromb Hoemost. 2017;117:1705• 1713.